Table 4.

Adverse Events (AEs) Occurring During Treatment

Adverse Events, n (%)	GS-9450 1 mg (n = 26)	5 mg (n = 26)	10 mg (n = 24)	40 mg (n = 25)	Placebo (n = 23)
No. of subjects with at least one AE	20 (77)	22 (85)	18 (75)	20 (80)	13 (57)
Total no. of events	62	64	67	60	48
Gastrointestinal disorders
Diarrhea	2 (8)	6 (23)	6 (25)	5 (20)	2 (9)
Nausea	3 (12)	1 (4)	3 (13)	3 (12)	1 (4)
Abdominal pain upper	1 (4)	1 (4)	4 (17)	1 (4)	0
Abdominal pain	1 (4)	2 (8)	1 (4)	1 (4)	1 (4)
Dyspepsia	2 (8)	2 (8)	1 (4)	1 (4)	0
Constipation	2 (8)	0	0	2 (8)	1 (4)
Dry mouth	1 (4)	0	2 (8)	1 (4)	0
Gastroesophageal reflux disease	0	0	0	3 (12)	1 (4)
General disorders and administration site conditions
Fatigue	6 (23)	5 (19)	2 (8)	2 (8)	5 (22)
Asthenia	1 (4)	1 (4)	1 (4)	0	1 (4)
Infections and infestations
Nasopharyngitis	2 (8)	0	0	2 (8)	1 (4)
Musculoskeletal and connective tissue disorders
Arthralgia	1 (4)	3 (12)	1 (4)	3 (12)	0
Back pain	1 (4)	2 (8)	0	1 (4)	2 (9)
Pain in extremity	1 (4)	0	1 (4)	2 (8)	0
Nervous system disorders
Headache	4 (15)	7 (27)	4 (17)	4 (16)	5 (22)
Dizziness	2 (8)	0	0	2 (8)	1 (4)
Somnolence	1 (4)	2 (8)	0	0	0